Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.

Liu S, Chen RX, Li J, Zhang Y, Wang XD, Fu Q, Chen LY, Liu XM, Huang HB, Huang M, Wang CX, Li JL.

Acta Pharmacol Sin. 2016 Sep;37(9):1251-8. doi: 10.1038/aps.2016.77. Epub 2016 Aug 8.

2.

Functional POR A503V is associated with the risk of bladder cancer in a Chinese population.

Xiao X, Ma G, Li S, Wang M, Liu N, Ma L, Zhang Z, Chu H, Zhang Z, Wang SL.

Sci Rep. 2015 Jun 30;5:11751. doi: 10.1038/srep11751.

3.

Multigene predictors of tacrolimus exposure in kidney transplant recipients.

Pulk RA, Schladt DS, Oetting WS, Guan W, Israni AK, Matas AJ, Remmel RP, Jacobson PA; DeKAF Investigators.

Pharmacogenomics. 2015 Jul;16(8):841-54. doi: 10.2217/pgs.15.42. Epub 2015 Jun 12.

4.
5.

Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort.

Tomková M, Panda SP, Šeda O, Baxová A, Hůlková M, Siler Masters BS, Martásek P.

Pharmacogenomics. 2015;16(3):205-15. doi: 10.2217/pgs.14.169.

6.

Role of protein-protein interactions in cytochrome P450-mediated drug metabolism and toxicity.

Kandel SE, Lampe JN.

Chem Res Toxicol. 2014 Sep 15;27(9):1474-86. doi: 10.1021/tx500203s. Epub 2014 Aug 29. Review.

7.

Pharmacogenetics in Jewish populations.

Yang Y, Peter I, Scott SA.

Drug Metabol Drug Interact. 2014;29(4):221-33. doi: 10.1515/dmdi-2013-0069. Review.

8.

Pharmacogenomics of human P450 oxidoreductase.

Pandey AV, Sproll P.

Front Pharmacol. 2014 May 9;5:103. doi: 10.3389/fphar.2014.00103. eCollection 2014. Review.

9.

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.

Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Åsberg A, Christensen H.

Eur J Clin Pharmacol. 2014 Jun;70(6):685-93.

10.

Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem.

Klein K, Zanger UM.

Front Genet. 2013 Feb 25;4:12. doi: 10.3389/fgene.2013.00012. eCollection 2013.

11.

Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.

Chen X, Pan LQ, Naranmandura H, Zeng S, Chen SQ.

PLoS One. 2012;7(6):e38495. doi: 10.1371/journal.pone.0038495. Epub 2012 Jun 12.

12.

Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations.

Tomková M, Marohnic CC, Gurwitz D, Seda O, Masters BS, Martásek P.

Pharmacogenomics. 2012 Apr;13(5):543-54. doi: 10.2217/pgs.12.21.

13.

Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system.

Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M.

Drug Metab Dispos. 2012 Apr;40(4):754-60. doi: 10.1124/dmd.111.042820. Epub 2012 Jan 17.

14.

High-yield expression of a catalytically active membrane-bound protein: human P450 oxidoreductase.

Sandee D, Miller WL.

Endocrinology. 2011 Jul;152(7):2904-8. doi: 10.1210/en.2011-0230. Epub 2011 May 17.

15.

Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Zhang X, Li L, Ding X, Kaminsky LS.

Drug Metab Dispos. 2011 Aug;39(8):1433-9. doi: 10.1124/dmd.111.038836. Epub 2011 May 11.

16.

Consequences of POR mutations and polymorphisms.

Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, Morrissey K, Giacomini KM.

Mol Cell Endocrinol. 2011 Apr 10;336(1-2):174-9. doi: 10.1016/j.mce.2010.10.022. Epub 2010 Nov 9.

17.

The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Miller WL, Auchus RJ.

Endocr Rev. 2011 Feb;32(1):81-151. doi: 10.1210/er.2010-0013. Epub 2010 Nov 4. Review. Erratum in: Endocr Rev. 2011 Aug;32(4):579.

Items per page

Supplemental Content

Write to the Help Desk